Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, May 1998, p. 1068-1072, Vol. 42, No. 5
Institut National de la Santé et de la
Recherche Médicale Unité 13 Hôpital Bichat-Claude
Bernard,1
Laboratoire de
Parasitologie-Mycologie,
Received 19 September 1997/Returned for modification 8 December
1997/Accepted 3 February 1998
We present a new experimental model for the simultaneous evaluation
of the activities of drugs against Pneumocystis
carinii, Toxoplasma gondii, and Mycobacterium
avium complex infections. Rats latently infected with
P. carinii were challenged with the MO-1 strain of
M. avium and then immunosuppressed with corticosteroids for
7 weeks. At week 5 the RH strain of T. gondii was
intraperitoneally injected. Organs were examined for the three
pathogens after death or killing of the animals at week 7. Without
treatment, rats challenged with T. gondii died
with pulmonary P. carinii infection and disseminated T. gondii and M. avium infections. In order to
assess the value of the model for evaluation of the activities of
drugs, we administered by oral gavage for 7 weeks drugs or combinations
of drugs selected for their individual efficacies against at least one
pathogen. We found that clarithromycin with sulfamethoxazole,
clarithromycin with atovaquone, roxithromycin with sulfamethoxazole or
dapsone, and rifabutin with atovaquone were effective against the three infections, whereas PS-15 with dapsone and trimethoprim with
sulfamethoxazole were active against Toxoplasma and
Pneumocystis infections only. This triple-infection rat
model offers a new tool for the simultaneous evaluation of the
activities of drugs against three of the major opportunistic infections
occurring in immunosuppressed individuals.
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Drug Evaluation of Concurrent Pneumocystis
carinii, Toxoplasma gondii, and Mycobacterium
avium Complex Infections in a Rat Model
*
Corresponding author. Mailing address: INSERM U 13, Hôpital Bichat-Claude Bernard, 46 rue Henri Huchard, 75877 Paris
Cedex 18, France. Phone: 33 1 40 25 86 05. Fax: 33 1 40 25 86 02. E-mail: u13bcb{at}magic.fr.
Antimicrobial Agents and Chemotherapy, May 1998, p. 1068-1072, Vol. 42, No. 5
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |